Nasdaq · CIK 0001514183
SILO Silo Pharma, Inc.
Insider trading from SEC Form 4. Last filing Dec 16, 2025. Close $1.49 on Oct 12, 2026, +3% from the 52-week low and -85% from the high.
In brief
Silo Pharma, Inc. (SILO) has 18 SEC Form 4 filings on file from 5 insiders, the latest filed on Dec 16, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
13 open-market trades have been scored at SILO. The newest: Eric Weisblum (Chief Executive Officer) bought $2,075 of stock on Dec 15, 2025, filed Dec 16, 2025, scored 38 (weak). The largest of the 13 shown: Eric Weisblum (CEO and President) bought $6,948 on Nov 20, 2023, scored 33 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Silo Pharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Eric Weisblum Chief Executive Officer buy | $2,075 5,000 shares | +2% | +11% from low-80% from high | |
| 43Moderate | Eric Weisblum Chief Executive Officer buy | $735 2,000 shares | +1% | 0% from low-82% from high | |
| 46Moderate | Eric Weisblum Chief Executive Officer buy | $4,847 12,000 shares | +6% | +2% from low-79% from high | |
| 46Moderate | Eric Weisblum Chief Executive Officer buy | $4,329 10,000 shares | +5% | +4% from low-78% from high | |
| 30Weak | Eric Weisblum CEO and President buy | $2,097 2,500 shares | +1% | - | |
| 25Weak | Eric Weisblum CEO and President buy | $4,625 5,000 shares | +3% | - | |
| 28Weak | Eric Weisblum CEO and President buy | $1,137 700 shares | +0% | +23% from low-53% from high | |
| 28Weak | Eric Weisblum CEO and President buy | $1,668 1,100 shares | +1% | +15% from low-56% from high | |
| 38Weak | Eric Weisblum CEO and President buy | $1,376 1,000 shares | +1% | +7% from low-62% from high | |
| 33Weak | Eric Weisblum CEO and President buy | $3,100 2,000 shares | +1% | +22% from low-57% from high | |
| 28Weak | Eric Weisblum CEO and President buy | $1,117 650 shares | +0% | +39% from low-51% from high | |
| 33Weak | Eric Weisblum CEO and President buy | $6,948 4,350 shares | +3% | +25% from low-56% from high | |
| 28Weak | Eric Weisblum CEO and President buy | $4,235 2,900 shares | +2% | +15% from low-60% from high |
Transactions
Every row filed, 30 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Eric Weisblum Chief Executive Officer | POpen-market purchase Common Stock | +2,500 | $0.41 | $1,025 | 214,432 | Dec 16, 2025 |
| Dec 15, 2025 | Eric Weisblum Chief Executive Officer | POpen-market purchase Common Stock | +2,500 | $0.42 | $1,050 | 216,932 | Dec 16, 2025 |
| Nov 20, 2025 | Eric Weisblum Chief Executive Officer | POpen-market purchase Common Stock | +1,000 | $0.37 | $370 | 210,932 | Nov 21, 2025 |
| Nov 21, 2025 | Eric Weisblum Chief Executive Officer | POpen-market purchase Common Stock | +1,000 | $0.37 | $365 | 211,932 | Nov 21, 2025 |
| Nov 18, 2025 | Eric Weisblum Chief Executive Officer | POpen-market purchase Common Stock | +7,500 | $0.40 | $3,025 | 205,432 | Nov 20, 2025 |
| Nov 19, 2025 | Eric Weisblum Chief Executive Officer | POpen-market purchase Common Stock | +4,500 | $0.41 | $1,823 | 209,932 | Nov 20, 2025 |
| May 27, 2025 | Eric Weisblum Chief Executive Officer | POpen-market purchase Common Stock | +10,000 | $0.43 | $4,329 | 197,932 | May 28, 2025 |
| May 23, 2025 | Kevin Munoz director | AGrant or award Options (right to buy)derivative | +50,000 | $0.00 | $0 | 53,425 | May 27, 2025 |
| May 23, 2025 | Eric Weisblum Chief Executive Officer | AGrant or award Options (right to buy)derivative | +200,000 | $0.00 | $0 | 387,932 | May 27, 2025 |
| May 23, 2025 | Daniel E. Ryweck Chief Financial Officer | AGrant or award Options (right to buy)derivative | +50,000 | $0.00 | $0 | 55,000 | May 27, 2025 |
| May 23, 2025 | Jeff Pavell director | AGrant or award Options (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 27, 2025 |
| May 23, 2025 | Wayne Linsley director | AGrant or award Options (right to buy)derivative | +50,000 | $0.00 | $0 | 53,425 | May 27, 2025 |
| Dec 13, 2024 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +2,500 | $0.84 | $2,097 | 187,932 | Dec 16, 2024 |
| Nov 20, 2024 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +2,500 | $0.95 | $2,375 | 182,932 | Nov 22, 2024 |
| Nov 22, 2024 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +2,500 | $0.90 | $2,250 | 185,432 | Nov 22, 2024 |
| Dec 19, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +500 | $1.63 | $815 | 169,724 | Dec 21, 2023 |
| Dec 20, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +200 | $1.61 | $322 | 169,924 | Dec 21, 2023 |
| Dec 14, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +200 | $1.50 | $300 | 168,324 | Dec 18, 2023 |
| Dec 15, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +900 | $1.52 | $1,368 | 169,224 | Dec 18, 2023 |
| Dec 5, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +600 | $1.39 | $834 | 167,724 | Dec 7, 2023 |
| Dec 6, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +76 | $1.34 | $102 | 167,800 | Dec 7, 2023 |
| Dec 7, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +324 | $1.36 | $441 | 168,124 | Dec 7, 2023 |
| Nov 29, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +1,000 | $1.57 | $1,570 | 166,124 | Nov 30, 2023 |
| Nov 30, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +1,000 | $1.53 | $1,530 | 167,124 | Nov 30, 2023 |
| Nov 22, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +400 | $1.68 | $672 | 164,874 | Nov 27, 2023 |
| Nov 27, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +250 | $1.78 | $445 | 165,124 | Nov 27, 2023 |
| Nov 20, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +4,050 | $1.60 | $6,480 | 164,174 | Nov 22, 2023 |
| Nov 21, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +300 | $1.56 | $468 | 164,474 | Nov 22, 2023 |
| Nov 16, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +1,100 | $1.33 | $1,463 | 158,324 | Nov 20, 2023 |
| Nov 17, 2023 | Eric Weisblum CEO and President | POpen-market purchase Common Stock | +1,800 | $1.54 | $2,772 | 160,124 | Nov 20, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Wayne Linsleydirector
- Kevin Munozdirector
- Jeff Pavelldirector
- Daniel E. RyweckChief Financial Officer
- Eric WeisblumCEO and President
Questions about SILO
Answered from the filings on this page, as of the latest one.
Are insiders buying SILO?
No. In the last 90 days no insider at Silo Pharma, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SILO on the open market?
Eric Weisblum (Chief Executive Officer) bought $2,075 of SILO on Dec 15, 2025 and filed the Form 4 on Dec 16, 2025. InsiderTell scored 38 (weak).
How many insiders file Form 4 at Silo Pharma, Inc.?
5 people have filed a Form 4 at Silo Pharma, Inc., among them Wayne Linsley (director), Kevin Munoz (director), Jeff Pavell (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.